Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Camprubí, Daniel
Almuedo Riera, Alex
Martí Soler, Helena
Soriano, Alex
Hurtado, Juan Carlos
Subirà, Carme
Grau Pujol, Berta
Krolewiecki, Alejandro Javier
Muñoz, José

Open link

Publication date

November 2020

DOI

10.1371/journal.pone.0242184

Publisher

Public Library of Science (PLoS)

Journal

PLoS ONE

Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.Fil: Camprubí, Daniel. Universidad de Barcelona; EspañaFil: Almuedo Riera, Alex. Universidad de Barcelona; EspañaFil: Martí Soler, Helena. Universidad de Barcelona; EspañaFil: Soriano, Alex. Universidad de Barcelona; EspañaFil: Hurtado, Juan Carlos. Universidad de Barcelona; EspañaFil: Subirà, Carme. Universidad de Barcelona; EspañaFil: ...